microRNA-21 Governs TORC1 Activation in Renal Cancer Cell Proliferation and Invasion

Metastatic renal cancer manifests multiple signatures of gene expression. Deviation in expression of mature miRNAs has been linked to human cancers. Importance of miR-21 in renal cell carcinomas is proposed from profiling studies using tumor tissue samples. However, the role of miR-21 function in causing renal cancer cell proliferation and invasion has not yet been shown. Using cultured renal carcinoma cells, we demonstrate enhanced expression of mature miR-21 along with pre-and pri-miR-21 by increased transcription compared to normal proximal tubular epithelial cells. Overexpression of miR-21 Sponge to quench endogenous miR-21 levels inhibited proliferation, migration and invasion of renal cancer cells. In the absence of mutation in the PTEN tumor suppressor gene, PTEN protein levels are frequently downregulated in renal cancer. We show that miR-21 targets PTEN mRNA 3′untranslated region to decrease PTEN protein expression and augments Akt phosphorylation in renal cancer cells. Downregulation of PTEN as well as overexpression of constitutively active Akt kinase prevented miR-21 Sponge-induced inhibition of renal cancer cell proliferation and migration. Moreover, we show that miR-21 Sponge inhibited the inactivating phosphorylation of the tumor suppressor protein tuberin and attenuated TORC1 activation. Finally, we demonstrate that expression of constitutively active TORC1 attenuated miR-21 Sponge-mediated suppression of proliferation and migration of renal cancer cells. Our results uncover a layer of post-transcriptional regulation of PTEN by transcriptional activation of miR-21 to force the canonical oncogenic Akt/TORC1 signaling conduit to drive renal cancer cell proliferation and invasion.

[1]  S. Signoretti,et al.  The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma , 2010, Clinical Cancer Research.

[2]  M. Michael,et al.  The VHL-dependent regulation of microRNAs in renal cancer , 2010, BMC medicine.

[3]  J. Avruch,et al.  Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action , 2002, Cell.

[4]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[5]  F. Monzon,et al.  Molecular Classification of Adult Renal Epithelial Neoplasms Using MicroRNA Expression and Virtual Karyotyping , 2011, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[6]  Tushar Patel,et al.  Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. , 2006, Gastroenterology.

[7]  Anna M. Krichevsky,et al.  miR-21: a small multi-faceted RNA , 2008, Journal of cellular and molecular medicine.

[8]  E. Abraham,et al.  Identification of a microRNA signature in renal fibrosis: role of miR-21. , 2011, American journal of physiology. Renal physiology.

[9]  Bin Tean Teh,et al.  MicroRNA profiling of human kidney cancer subtypes. , 2009, International journal of oncology.

[10]  Kenneth M. Yamada,et al.  Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. , 1998, Science.

[11]  A. Hinnebusch,et al.  Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets , 2009, Cell.

[12]  S. Signoretti,et al.  VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400 , 2008, Nature Cell Biology.

[13]  F. Das,et al.  Mesangial Cell Hypertrophy by High Glucose Is Mediated by Downregulation of the Tumor Suppressor PTEN , 2006, Diabetes.

[14]  A. Hata,et al.  SMAD proteins control DROSHA-mediated microRNA maturation , 2008, Nature.

[15]  Norbert Hollaender,et al.  Phase 3 trial of everolimus for metastatic renal cell carcinoma , 2010, Cancer.

[16]  Falguni Das,et al.  MicroRNA-21 Orchestrates High Glucose-induced Signals to TOR Complex 1, Resulting in Renal Cell Pathology in Diabetes* , 2011, The Journal of Biological Chemistry.

[17]  F. Luan,et al.  Rapamycin is an effective inhibitor of human renal cancer metastasis. , 2003, Kidney international.

[18]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[19]  W. Kaelin Treatment of kidney cancer , 2009, Cancer.

[20]  K. Ghoshal,et al.  MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. , 2007, Gastroenterology.

[21]  Shunyou Wang,et al.  PTENless means more. , 2004, Developmental biology.

[22]  L. Skoog,et al.  PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer , 2007, Clinical Cancer Research.

[23]  P. Tamboli,et al.  The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases , 2011, Cancer.

[24]  A. Hata,et al.  Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. , 2010, Molecular cell.

[25]  M. Loda,et al.  Identification of the miR-106b~25 MicroRNA Cluster as a Proto-Oncogenic PTEN-Targeting Intron That Cooperates with Its Host Gene MCM7 in Transformation , 2010, Science Signaling.

[26]  S. Saal,et al.  MicroRNAs and the kidney: coming of age , 2009, Current opinion in nephrology and hypertension.

[27]  Nobuyuki Shishido,et al.  Mice Lacking p27 Kip1 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors , 1996, Cell.

[28]  A. López-Guillermo,et al.  MicroRNA expression profiling in classic Hodgkin lymphoma. , 2008, Blood.

[29]  Shuomin Zhu,et al.  miR-21-mediated tumor growth , 2007, Oncogene.

[30]  M. Hall,et al.  Activation of mTORC 2 by Association with the Ribosome , 2011 .

[31]  W. Kaelin The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer , 2008, Nature Reviews Cancer.

[32]  J. Iacomini,et al.  Identification of a microRNA signature of renal ischemia reperfusion injury , 2010, Proceedings of the National Academy of Sciences.

[33]  M. Milowsky,et al.  Chemotherapeutic strategies for renal cell carcinoma. , 2003, The Urologic clinics of North America.

[34]  Paul J. Williams,et al.  NAD(P)H Oxidases Regulate HIF-2α Protein Expression* , 2007, Journal of Biological Chemistry.

[35]  J. Herman,et al.  Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers , 1998, Oncogene.

[36]  T. Yoneda,et al.  Simvastatin Prevents Skeletal Metastasis of Breast Cancer by an Antagonistic Interplay between p53 and CD44* , 2011, The Journal of Biological Chemistry.

[37]  Margaret S. Ebert,et al.  MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells , 2007, Nature Methods.

[38]  H. Gómez,et al.  The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer , 2010, Cancer and Metastasis Reviews.

[39]  J. Blenis,et al.  Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. , 2002, Molecular cell.

[40]  T. Maeda,et al.  Isolation of Hyperactive Mutants of Mammalian Target of Rapamycin* , 2008, Journal of Biological Chemistry.

[41]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[42]  H. Abboud,et al.  TSC2 Deficiency Increases PTEN via HIF1α* , 2009, The Journal of Biological Chemistry.

[43]  Lin He Posttranscriptional Regulation of PTEN Dosage by Noncoding RNAs , 2010, Science Signaling.

[44]  Lewis C Cantley,et al.  Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. , 2005, Genes & development.

[45]  Hongyu Zhou,et al.  mTOR signaling in cancer cell motility and tumor metastasis. , 2010, Critical reviews in eukaryotic gene expression.

[46]  H. Abboud,et al.  Resveratrol inhibits PDGF receptor mitogenic signaling in mesangial cells: role of PTP1B , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  Tomohiko Maehama,et al.  The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate* , 1998, The Journal of Biological Chemistry.

[48]  D. Sabatini,et al.  mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.

[49]  E. Olson,et al.  Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. , 2010, Cancer cell.

[50]  Y Dai,et al.  Microarray analysis of microRNA expression in renal clear cell carcinoma. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[51]  P. A. van den Brandt,et al.  Genetic and Epigenetic Alterations in the von Hippel-Lindau Gene: the Influence on Renal Cancer Prognosis , 2008, Clinical Cancer Research.

[52]  Jennifer Couzin,et al.  MicroRNAs Make Big Impression in Disease After Disease , 2008, Science.

[53]  Xinjiang Wang,et al.  Post-translational regulation of PTEN , 2008, Oncogene.

[54]  A. Dominiczak,et al.  miR-21 and miR-214 are consistently modulated during renal injury in rodent models. , 2011, The American journal of pathology.

[55]  J. Crespo,et al.  Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. , 2002, Molecular cell.

[56]  Shile Huang,et al.  Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins , 2008, Oncogene.

[57]  T. Hunter,et al.  Inappropriate Activation of the TSC/Rheb/mTOR/S6K Cassette Induces IRS1/2 Depletion, Insulin Resistance, and Cell Survival Deficiencies , 2004, Current Biology.

[58]  C. Mandal,et al.  Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. , 2010, Cellular signalling.

[59]  E. Hafen,et al.  Living with Lethal PIP3 Levels: Viability of Flies Lacking PTEN Restored by a PH Domain Mutation in Akt/PKB , 2002, Science.

[60]  Dianqing Wu,et al.  Evidence for Direct Activation of mTORC2 Kinase Activity by Phosphatidylinositol 3,4,5-Trisphosphate* , 2011, The Journal of Biological Chemistry.

[61]  J. Blenis,et al.  Tuberous Sclerosis Complex Gene Products, Tuberin and Hamartin, Control mTOR Signaling by Acting as a GTPase-Activating Protein Complex toward Rheb , 2003, Current Biology.

[62]  Cornelis J. Weijer,et al.  Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN , 2009, Oncogene.

[63]  G. Bhanot,et al.  Identification of a microRNA panel for clear-cell kidney cancer. , 2010, Urology.

[64]  Marty W. Mayo,et al.  Akt Stimulates the Transactivation Potential of the RelA/p65 Subunit of NF-κB through Utilization of the IκB Kinase and Activation of the Mitogen-activated Protein Kinase p38* , 2001, The Journal of Biological Chemistry.

[65]  H. Abboud,et al.  Association and direct activation of signal transducer and activator of transcription1alpha by platelet-derived growth factor receptor. , 1998, The Journal of clinical investigation.

[66]  V. Zinzalla,et al.  Activation of mTORC2 by Association with the Ribosome , 2011, Cell.

[67]  F. Slack,et al.  OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma , 2010, Nature.

[68]  J. Blenis,et al.  Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways , 2006, Oncogene.

[69]  Min Cheol Lee,et al.  Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth , 2003, Journal of surgical oncology.

[70]  D. Guertin,et al.  Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.

[71]  Mitsuo Kato,et al.  MicroRNAs and their role in progressive kidney diseases. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[72]  M. Seto,et al.  Genome‐wide microRNA expression profiling in renal cell carcinoma: significant down‐regulation of miR‐141 and miR‐200c , 2008, The Journal of pathology.

[73]  S. Horvath,et al.  Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma , 2008, PLoS medicine.

[74]  S. Liou,et al.  Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[76]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[77]  P. Pandolfi,et al.  Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse , 2001, Nature Genetics.

[78]  F. Das,et al.  PRAS40 acts as a nodal regulator of high glucose‐induced TORC1 activation in glomerular mesangial cell hypertrophy , 2010, Journal of cellular physiology.

[79]  Y. Pekarsky,et al.  Reprogramming of miRNA networks in cancer and leukemia. , 2010, Genome research.

[80]  Tak W. Mak,et al.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.

[81]  Masafumi Ohtsubo,et al.  Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells , 2001, Oncogene.

[82]  Guoku Hu,et al.  Binding of NF-kappaB p65 subunit to the promoter elements is involved in LPS-induced transactivation of miRNA genes in human biliary epithelial cells , 2010, Nucleic acids research.

[83]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[84]  Hyung-Seok Kim,et al.  Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. , 2003 .

[85]  Masafumi Ohtsubo,et al.  Increased nuclear factor-kappa B activation is related to the tumor development of renal cell carcinoma. , 2003, Carcinogenesis.

[86]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[87]  Peter Bühlmann,et al.  Mining Tissue Microarray Data to Uncover Combinations of Biomarker Expression Patterns that Improve Intermediate Staging and Grading of Clear Cell Renal Cell Cancer , 2009, Clinical Cancer Research.

[88]  John E. Burke,et al.  Structural Basis for Activation and Inhibition of Class I Phosphoinositide 3-Kinases , 2011, Science Signaling.

[89]  I. Gout,et al.  The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins , 2004, The Journal of cell biology.

[90]  R. Loewith,et al.  Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive , 2004, Nature Cell Biology.

[91]  Jacquelyne S Poon,et al.  Both lipid- and protein-phosphatase activities of PTEN contribute to the p53-PTEN anti-invasion pathway , 2010, Cell cycle.

[92]  Ming Zhou,et al.  Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma , 2011, Genes, chromosomes & cancer.

[93]  L. Mahimainathan,et al.  Inactivation of Platelet-derived Growth Factor Receptor by the Tumor Suppressor PTEN Provides a Novel Mechanism of Action of the Phosphatase* , 2004, Journal of Biological Chemistry.

[94]  C. Taylor,et al.  Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. , 2006, Cancer research.

[95]  D. Riley,et al.  Raptor-rictor axis in TGFβ-induced protein synthesis , 2008 .

[96]  D. Riley,et al.  Raptor-rictor axis in TGFbeta-induced protein synthesis. , 2008, Cellular signalling.

[97]  Shamit Soneji,et al.  Microrna expression distinguishes between germinal center B cell‐like and activated B cell‐like subtypes of diffuse large B cell lymphoma , 2007, International journal of cancer.

[98]  R. Parsons,et al.  The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. , 2008, Cancer research.

[99]  Yurong Fu,et al.  Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues , 2010, Journal of Cancer Research and Clinical Oncology.

[100]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[101]  M. Doucet,et al.  Renal cell carcinoma bone metastasis—elucidating the molecular targets , 2007, Cancer and Metastasis Reviews.

[102]  J. Downward,et al.  Protein Kinase B Activation and Lamellipodium Formation Are Independent Phosphoinositide 3-Kinase-Mediated Events Differentially Regulated by Endogenous Ras , 1998, Molecular and Cellular Biology.

[103]  P. Dennis,et al.  PTEN loss in the continuum of common cancers, rare syndromes and mouse models , 2011, Nature Reviews Cancer.

[104]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[105]  O. Rouvière,et al.  Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up? , 2006, Nature Clinical Practice Oncology.

[106]  G. G. Choudhury,et al.  Fish oil targets PTEN to regulate NFκB for downregulation of anti-apoptotic genes in breast tumor growth , 2009, Breast Cancer Research and Treatment.

[107]  L. Cantley,et al.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[108]  Amy E Pasquinelli Paring MiRNAs Through Pairing , 2010, Science.

[109]  F. Waldman,et al.  Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors , 2008, Clinical Cancer Research.

[110]  K. Kosik,et al.  MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. , 2005, Cancer research.

[111]  S. Lowe,et al.  A microRNA polycistron as a potential human oncogene , 2005, Nature.

[112]  Pier Paolo Pandolfi,et al.  Tenets of PTEN Tumor Suppression , 2008, Cell.

[113]  A. Novick Kidney cancer: past, present, and future. , 2007, Urologic oncology.

[114]  E. Lai,et al.  Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants. , 2011, Molecular cell.

[115]  W. Filipowicz,et al.  Regulation of mRNA translation and stability by microRNAs. , 2010, Annual review of biochemistry.

[116]  Alice Shapiro,et al.  MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. , 2008, Cancer research.

[117]  Kenneth M. Yamada,et al.  Tumor Suppressor PTEN Inhibits Integrin- and Growth Factor–mediated Mitogen-activated Protein (MAP) Kinase Signaling Pathways , 1998, The Journal of cell biology.

[118]  George A Calin,et al.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. , 2008, JAMA.

[119]  D. Bartel MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[120]  W. Kaelin,et al.  Molecular basis of the VHL hereditary cancer syndrome , 2002, Nature Reviews Cancer.